Loading organizations...
§ Private Profile · Oxford, Oxfordshire, United Kingdom
Clinical-stage biotech developing targeted radiopharmaceutical therapies for prostate cancer, using PSMA-targeted assets.
Blue Earth Therapeutics is a clinical-stage biotechnology company based in Needham, Massachusetts, that develops next-generation targeted radiopharmaceutical therapies for the treatment of oncology patients. The organization focuses on delivering high radiation doses directly to tumors while sparing normal organs, advancing an initial clinical pipeline that targets prostate cancer through PSMA-targeted radiohybrid assets. Following its initial incubation, the enterprise completed a Series A venture financing round in 2024 to operate as a partial spin-out from Bracco Imaging, securing backing from investors including Soleus Capital. The firm leverages a joint United States and United Kingdom team alongside external manufacturing partners to advance its clinical programs, which include the development of pipeline assets such as the UKBET-rh-2500053 compound. Operating in parallel with its sister company Blue Earth Diagnostics, Blue Earth Therapeutics was founded in 2021 by David Gauden.
Blue Earth Therapeutics has raised $76.5M across 1 funding round.
Blue Earth Therapeutics has raised $76.5M in total across 1 funding round.
Blue Earth Therapeutics has raised $76.5M across 1 funding round. Most recently, it raised $76.5M Series A in October 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 31, 2024 | $76.5M Series A | Sands Capital, Soleus Capital | — | Announced |
Blue Earth Therapeutics has raised $76.5M in total across 1 funding round.
Blue Earth Therapeutics's investors include Sands Capital, Soleus Capital.